Fig. 2From: The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatmentCell cycle distribution of LN405 and T98G glioblastoma cell lines 4, 24 and 96 h after treatment with 0.25 μM SAR and/or 8 Gy irradiation. Data are means ± SEM from 3 independent experiments. Statistical significance compared to control is indicated by asterisks (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001)Back to article page